Jennifer Doudna (Photo by Brian Ach/Getty Images for Wired)
June 22, 2022 11:18 AM EDT
Discovery

Doud­na re­search team finds CRISPR-Csm de­liv­ery po­ten­tial­ly out­per­forms RNAi, Cas13

Paul Schloesser

Associate Editor

While RNAi and Cas13 have been used as some of the ear­ly meth­ods for gene si­lenc­ing, a new preprint from top …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times